Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neuroscience Pharma Spa currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, reflecting a concentrated prosecution strategy for the company. The portfolio's activity is situated within 1 distinct art unit, which suggests the underlying technology is focused in its technical classification. This concentration of 1 examiner and 1 art unit for the 1 pending action simplifies the prosecution landscape for this entity.
Isis A D Ghali is the busiest examiner for the company, currently overseeing 1 pending office action. This specific workload accounts for 1 of the 1 total pending actions for the portfolio. With 1 examiner and 1 art unit involved, the prosecution process is centralized. Practitioners should focus on the specific requirements of this single examiner, as their decisions will define the immediate success of the company's intellectual property efforts. This structure allows for a consistent response to the patent office without the need to reconcile different examiner preferences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GHALI, ISIS A D | 1 | 27.9% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022877 | FRUIT EXTRACTS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | GHALI, ISIS A D | 62d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022877 | FRUIT EXTRACTS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | GHALI, ISIS A D | 62d |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18022877 | FRUIT EXTRACTS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | GHALI, ISIS A D | 1611 | §103§112 | Non-Final OA | 62d | Pending | Feb 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial